S Budd Haeberlein, P S Aisen, F Barkhof, S Chalkias, T Chen, S Cohen, G Dent, O Hansson, K Harrison, C von Hehn, T Iwatsubo, C Mallinckrodt, C J Mummery, K K Muralidharan, I Nestorov, L Nisenbaum, R Rajagovindan, L Skordos, Y Tian, C H van Dyck, B Vellas, S Wu, Y Zhu, A Sandrock
BACKGROUND: Alzheimer's disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. OBJECTIVES: We evaluated the efficacy and safety of aducanumab in early Alzheimer's disease. DESIGN: EMERGE and ENGAGE were two randomized, double-blind, placebo-controlled, global, phase 3 studies of aducanumab in patients with early Alzheimer's disease...
2022: Journal of Prevention of Alzheimer's Disease